Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 576 - 600 of 14528 in total
Emicizumab is a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and it has the capacity to bind simultaneously to activated Factor IX and Factor X. The ability of Emicizumab to bind to all these three different factors allows it to overcome immunogenicity and unstable...
Approved
Investigational
Matched Description: … Ltd. and co-developed with Roche and Genentech.[L1015] ... it has the capacity to bind simultaneously to activated Factor IX and Factor X. ... a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Blood and Blood Forming Organs …
Cold agglutinin disease (CAD) is a type of autoimmune hemolytic anemia (AIHA) in which autoantibodies directed against red blood cell surface antigens cause hemolysis at low (3-4°C) temperatures.[A245154,L40114] This cold subtype accounts for approximately 15-25% of all AIHA and is more common in the elderly.[A245159,L40114] In approximately 90% of cases,...
Approved
Investigational
Matched Description: … [A245154,L40114] This cold subtype accounts for approximately 15-25% of all AIHA and is more common in ... IgM) autoantibodies towards the I antigen on erythrocytes - these antibodies react optimally at 4°C and ... is driven by complement activation, which initiates a cascade that ultimately leads to both intra- and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to tocilizumab, which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disorder of the central...
Approved
Matched Description: … [A218551] It received subsequent approvals in Switzerland and Japan,[A218551] and was approved for use ... interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and ... at least in part, by IL-6, including increased production of anti-aquaporin-4 (AQP4) autoantibodies and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible...
Approved
Matched Description: … neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic colorectal cancer with ... EGFR overexpression has been linked to more advanced disease and poor prognosis. ... cells; it is responsible for regulating epithelial tissue development and homeostasis. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Casein allergenic extract is used in allergenic testing.
Approved
Matched Categories: … Fluids and Secretions ... Diet, Food, and Nutrition ... Amino Acids, Peptides, and Proteins …
Becaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae. Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical polypeptide chains that are bound together...
Approved
Investigational
Matched Description: … Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins ... Preparations for Treatment of Wounds and Ulcers …
Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name...
Approved
Investigational
Matched Description: … in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids,[A225816] and ... [A225761] Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist ... [A225926] In May 2021, the FDA approved the combination product made up of relugolix, [estradiol], and
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... relugolix, estradiol and norethisterone …
Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis . The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy...
Approved
Investigational
Matched Description: … The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults ... The approved recommended dosage of ILUMYA is a subcutaneous injection of 100 mg at Weeks 0, 4, and every ... The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects [A32257 …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several parenteral antagonists...
Approved
Investigational
Matched Description: … [L41640] While several parenteral antagonists of CGRP and its receptor have been approved for migraine ... L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and ... was subsequently approved by the European Commission in April 2022 for both the treatment and prevention …
Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of...
Approved
Matched Categories: … Fluids and Secretions ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Ciclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a synthetic antifungal agent for topical dermatologic treatment of superficial mycoses. In particular, the agent is especially effective in treating Tinea versicolor.
Approved
Investigational
Matched Description: … Ciclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a …
Matched Categories: … Vaginal Creams, Foams, and Jellies ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
The respiratory protein of the red blood cells. It consists primarily of globin and heme.
Approved
Experimental
Investigational
Matched Description: … It consists primarily of globin and heme. …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Technetium Tc 99m Mebrofenin is a diagnostic radiopharmaceutical composed of diisopropyl-iminodiacetic acid (DISIDA) attached to a technetium-99m ion. Following intravenous injection, single photon emission computer tomography (SPECT) imaging of the liver or gallbladder is performed using a gamma camera to detect the gamma rays emitted by the technetium-99m as it...
Approved
Matched Description: … uptake and fast biliary excretion, resulting in improved hepatic imaging. ... More specifically, mebrofenin is taken up into hepatocytes through the action of OATP1B1 and OATP1B3 ... Currently available within a sterile kit, Tc-99m Mebrofenin is indicated for imaging of the liver and
Matched Categories: … Indicators and Reagents ... Amino Acids, Peptides, and Proteins ... Hepatic and Reticulo Endothelial System …
Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The result is polyclonal IgG that...
Approved
Investigational
Matched Description: … system proteins including lymphocyte surface proteins, granulocytes, platelets, bone marrow cells, and ... currently indicated for the suppression of the immune system to prevent renal transplant rejection and ... Induction of T cell apoptosis and resulting T-cell lymphopenia found in vivo is credited for its therapeutic …
Matched Categories: … Fluids and Secretions ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Intravenous susoctocog alfa is a recombinant, B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) product that has recently been approved for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA). AHA is a rare bleeding disorder that results in a prolonged clotting time as measured by the...
Approved
Investigational
Matched Description: … These autoantibodies neutralize circulating human factor VIII and create a functional deficiency of this ... Susoctocog alfa was approved by the FDA in October 2014 and is marketed under the brand name Obizur for ... porcine FVIII treatment approved for AHA that allows physicians to manage the treatment's efficacy and
Matched Categories: … Blood and Blood Forming Organs …
Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. One such ADC is sacituzumab govitecan, which combines a humanized anti-trophoblast cell-surface antigen 2...
Approved
Investigational
Matched Description: … Commission and Health Canada respectively. ... [L13002, A193674] Sacituzumab govitecan was granted FDA approval on April 22nd, 2020 and is marketed ... [A193653] In November 2021 and July 20 2023, sacituzumab govitecan was also approved by the European …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Eculizumab is a monoclonal antibody that targets complement protein C5.[L6919,A2245] Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.[L6919,A2245,A2246] Eculizumab was granted FDA approval on 16 March 2007. In Q1 2023, the EMA's Committee for Medicinal Products...
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Mifamurtide is an immunomodulator with antitumor activity via activation of macrophages and monocytes. Also called L-MTP-PE, mifamurtide may be a liposomal form of of the active ingredient MTP-PE, which is a synthetic, less pyrogenic, and longer-acting derivative of muramyl dipeptide (MDP). MDP is a motif present in all gram-positive and...
Approved
Experimental
Matched Description: … receptors (NLRs) and toll-like receptors present in macrophages and monocytes. ... signalling molecules and activators such as nucleotide-binding and oligomerization domain (NOD)-like ... of bactericidal and tumoricidal effects [A31745]. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding . Linagliptin was approved by...
Approved
Matched Description: … that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and
Matched Categories: … Alimentary Tract and Metabolism ... metformin and linagliptin ... linagliptin and empagliflozin ... metformin, linagliptin and empagliflozin ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Buclizine is an antihistamine medication with both antiemetic and anticholinergic effects , belonging to the piperazine derivative family of drugs. It was manufactured by Stuart Pharms and initially approved by the FDA in 1957. Following this, it was touted to be effective as an appetite stimulant in children when administered...
Approved
Matched Description: … in the treatment of nausea and vomiting during pregnancy. ... It was manufactured by Stuart Pharms and initially approved by the FDA in 1957. ... Buclizine is an antihistamine medication with both antiemetic and anticholinergic effects [L6220], belonging …
Matched Salts name: … Buclizine hydrochloride
Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical". . This low affinity to dopamine receptors results in fewer extrapyramidal side effects,...
Approved
Matched Description: … side effects, notably gastrointestinal hypomotility and orthostatic hypotension. ... [A185747] However, its promiscuity toward the muscarinic and adrenergic receptors can result in other ... Despite its effectiveness in treating both positive and negative symptoms of schizophrenia, clozapine …
Matched Salts name: … Clozapine hydrochloride
Matched Categories: … Diazepines, Oxazepines, Thiazepines and Oxepines …
Remoxipride is an atypical antipsychotic agent that is specific for dopamine D2 receptors. It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]
Approved
Withdrawn
Matched Salts name: … Remoxipride hydrochloride
Matched Categories: … Benzamides and benzamide derivatives …
Miglustat, commonly marketed under the trade name Zavesca, is a drug used to treat Gaucher disease. It inhibits the enzyme glucosylceramide synthase, an essential enzyme for the synthesis of most glycosphingolipids. It is only used for patients who cannot be treated with enzyme replacement therapy with imiglucerase. Miglustat is now...
Approved
Matched Description: … patients in the European Union, Brazil, and South Korea. ... Miglustat is now the first and only approved therapy for patients with Niemann-Pick disease type C (NP-C ... It has recently been approved for treatment of progressive neurological symptoms in adult and pediatric …
Matched Salts name: … Miglustat hydrochloride
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …
A phenothiazine used as an antipsychotic agent and as an antiemetic.
Approved
Vet approved
Matched Description: … A phenothiazine used as an antipsychotic agent and as an antiemetic. …
Matched Salts name: … Triflupromazine hydrochloride
An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also...
Approved
Matched Description: … It also potentiates the effect of other antiulcer agents such as cimetidine and ranitidine. ... It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the ... required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and
Matched Salts name: … Pirenzepine hydrochloride
Matched Categories: … Alimentary Tract and Metabolism ... Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) …
Displaying drugs 576 - 600 of 14528 in total